April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
RBC Fatty Acids Analysis for Determining Compliance with Omega-3 Supplements
Author Affiliations & Notes
  • Peter G. Dentone
    Ophthalmology, Mount Sinai School of Medicine, New York, New York
  • Maureen G. Maguire
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania
  • Ellen Peskin
    Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania
  • Ann Moser
    Neurology, Kennedy Krieger Institute, Baltimore, Maryland
  • Penny A. Asbell
    Ophthalmology, Mount Sinai School of Medicine, New York, New York
  • Footnotes
    Commercial Relationships  Peter G. Dentone, None; Maureen G. Maguire, None; Ellen Peskin, None; Ann Moser, None; Penny A. Asbell, None
  • Footnotes
    Support  Supported in part by the National Eye Institute/National Institutes of Health (1-R34-EY017626-01A2) as well as by The Martin and Toni Sosnoff Foundation.
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4318. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peter G. Dentone, Maureen G. Maguire, Ellen Peskin, Ann Moser, Penny A. Asbell; RBC Fatty Acids Analysis for Determining Compliance with Omega-3 Supplements. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4318.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To assess subject compliance with oral omega-3 fatty acids (ω-3FA) supplements (fish oil) and placebo (olive oil) using pill counts and red blood cell (RBC) membrane total lipid FA profiles and to compare the 2 assessment techniques.

Methods: : 16 Subjects were given oral ω-3FA supplements or placebo (5 capsules/day) for 3 months. All subjects were instructed to return any unused capsules at the end of 3 months. Blood drawn at baseline and 3 months was analyzed in a masked fashion for RBC membrane total lipid FA content. Blood was collected in 4mL tubes containing EDTA and analyzed the next day for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) levels (% total FA), for arachidonic acid (AA) which is replaced by EPA and DHA in the cell membrane, and for oleic acid (OA) levels (% total FA) present in olive oil. Wilcoxon signed-rank tests and rank-sum tests were used to compare changes from baseline and to compare the between treatment groups; Spearman correlation coefficients were used to assess the relationship of pill counts to changes in FAs.

Results: : Pill counts for the ω-3 (N=7) and placebo (N=9) groups showed a mean consumption of 4.39 and 4.76 pills / day, respectively. In the ω-3 group, the median change from baseline was +1.46% for EPA (p=0.03), +1.49% for DHA (p=0.08), -1.91% for AA (p=0.02), and -0.50 for OA levels (p=0.11). In the placebo group, median changes in all measured FAs were small and not statistically significant (EPA: 0.05%, p=0.25; DHA: 0.25%, p=0.43; AA: -0.23%, p=0.16; OA: -0.60%, p=0.16). Changes in FA levels were significantly greater in the ω-3 group for EPA (p=0.01) and AA (p=0.04). The correlations between the number of pills taken in the ω-3 group and changes in EPA (r=0.36, p=0.43) and DHA (r=0.17, p=0.70) levels were not strong.

Conclusions: : Both groups showed good compliance as measured by pill counts with no significant difference. Subjects in the ω-3 group showed increases in EPA (significant) and DHA (not significant) along with a significant decrease in AA, as expected. These trends were not seen in the placebo group. The low correlation between pill counts and blood levels suggests pill counts alone do not accurately capture compliance and are not a replacement for blood tests in assessment of compliance in studies of ω-3 supplements.

Clinical Trial: : http://www.clinicaltrials.gov NCT01102257

Keywords: clinical research methodology • clinical laboratory testing • nutritional factors 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.